Estevens R, Mil-Homens D, Fialho A
Microorganisms. 2023; 11(5).
PMID: 37317093
PMC: 10224339.
DOI: 10.3390/microorganisms11051118.
Alsowayeh N, Albutti A, Al-Shouli S
Front Microbiol. 2022; 13:929400.
PMID: 35875518
PMC: 9297367.
DOI: 10.3389/fmicb.2022.929400.
Sabet M, Griffith D
Antimicrob Agents Chemother. 2019; 64(2).
PMID: 31712215
PMC: 6985725.
DOI: 10.1128/AAC.01988-19.
Horikawa T, Hung L, Kim H, Shaya D, Kim C, Terwilliger T
Acta Crystallogr F Struct Biol Commun. 2018; 74(Pt 11):710-716.
PMID: 30387776
PMC: 6213979.
DOI: 10.1107/S2053230X18013547.
Orava C, FitzGerald J, Figliomeni S, Lam D, Naccarato A, Szego E
Physiother Can. 2018; 70(1):42-48.
PMID: 29434417
PMC: 5802957.
DOI: 10.3138/ptc.2016-75.
Efficient management and maintenance of ultrasonic nebulizers to prevent microbial contamination.
Ida Y, Ohnishi H, Araki K, Saito R, Kawai S, Watanabe T
World J Methodol. 2016; 6(1):126-32.
PMID: 27019804
PMC: 4804248.
DOI: 10.5662/wjm.v6.i1.126.
Reducing virulence of the human pathogen Burkholderia by altering the substrate specificity of the quorum-quenching acylase PvdQ.
Koch G, Nadal-Jimenez P, Reis C, Muntendam R, Bokhove M, Melillo E
Proc Natl Acad Sci U S A. 2014; 111(4):1568-73.
PMID: 24474783
PMC: 3910591.
DOI: 10.1073/pnas.1311263111.
Burkholderia cenocepacia bacteremia without respiratory colonization in an adult intensive care unit: epidemiological and molecular investigation of an outbreak.
Katsiari M, Roussou Z, Tryfinopoulou K, Vatopoulos A, Platsouka E, Maguina A
Hippokratia. 2013; 16(4):317-23.
PMID: 23935310
PMC: 3738605.
Advances in electronic-nose technologies developed for biomedical applications.
Wilson A, Baietto M
Sensors (Basel). 2012; 11(1):1105-76.
PMID: 22346620
PMC: 3274093.
DOI: 10.3390/s110101105.
Pseudomonas aeruginosa and cystic fibrosis: Antibiotic therapy and the science behind the magic.
MacDonald N
Can J Infect Dis. 2012; 8(6):335-42.
PMID: 22346530
PMC: 3250901.
DOI: 10.1155/1997/617690.
A case of native valve endocarditis caused by Burkholderia cepacia without predisposing factors.
Ki H, Kim S, Han S, Cheong H
BMC Infect Dis. 2011; 11:114.
PMID: 21548997
PMC: 3112426.
DOI: 10.1186/1471-2334-11-114.
The type 2 secretion Pseudopilin, gspJ, is required for multihost pathogenicity of Burkholderia cenocepacia AU1054.
Somvanshi V, Viswanathan P, Jacobs J, Mulks M, Sundin G, Ciche T
Infect Immun. 2010; 78(10):4110-21.
PMID: 20660607
PMC: 2950340.
DOI: 10.1128/IAI.00558-10.
Genetic diversity and multihost pathogenicity of clinical and environmental strains of Burkholderia cenocepacia.
Springman A, Jacobs J, Somvanshi V, Sundin G, Mulks M, Whittam T
Appl Environ Microbiol. 2009; 75(16):5250-60.
PMID: 19542323
PMC: 2725458.
DOI: 10.1128/AEM.00877-09.
Ten years of bacterial genome sequencing: comparative-genomics-based discoveries.
Binnewies T, Motro Y, Hallin P, Lund O, Dunn D, La T
Funct Integr Genomics. 2006; 6(3):165-85.
PMID: 16773396
DOI: 10.1007/s10142-006-0027-2.
Enterococcus faecalis mammalian virulence-related factors exhibit potent pathogenicity in the Arabidopsis thaliana plant model.
Jha A, Bais H, Vivanco J
Infect Immun. 2004; 73(1):464-75.
PMID: 15618186
PMC: 538936.
DOI: 10.1128/IAI.73.1.464-475.2005.
Outbreak of Burkholderia cepacia bacteremia in a pediatric hospital due to contamination of lipid emulsion stoppers.
Doit C, Loukil C, Simon A, Ferroni A, Fontan J, Bonacorsi S
J Clin Microbiol. 2004; 42(5):2227-30.
PMID: 15131197
PMC: 404641.
DOI: 10.1128/JCM.42.5.2227-2230.2004.
Clinical outcome after acquisition of Burkholderia cepacia in patients with cystic fibrosis.
McCloskey M, McCaughan J, REDMOND A, Elborn J
Ir J Med Sci. 2001; 170(1):28-31.
PMID: 11440408
DOI: 10.1007/BF03167716.
Lipopolysaccharide of Burkholderia cepacia and its unique character to stimulate murine macrophages with relative lack of interleukin-1beta-inducing ability.
Shimomura H, Matsuura M, Saito S, Hirai Y, Isshiki Y, Kawahara K
Infect Immun. 2001; 69(6):3663-9.
PMID: 11349028
PMC: 98363.
DOI: 10.1128/IAI.69.6.3663-3669.2001.
An epidemic of burkholderia cepacia transmitted between patients with and without cystic fibrosis.
Holmes A, Nolan R, Taylor R, Finley R, Riley M, Jiang R
J Infect Dis. 1999; 179(5):1197-205.
PMID: 10191223
PMC: 3325287.
DOI: 10.1086/314699.
Lipopolysaccharide (LPS) from Burkholderia cepacia is more active than LPS from Pseudomonas aeruginosa and Stenotrophomonas maltophilia in stimulating tumor necrosis factor alpha from human monocytes.
Zughaier S, Ryley H, Jackson S
Infect Immun. 1999; 67(3):1505-7.
PMID: 10024601
PMC: 96487.
DOI: 10.1128/IAI.67.3.1505-1507.1999.